Trends in Mid-sized European Licensing
Executive Summary
Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.
You may also be interested in...
Trends in Mid-sized European Licensing
On balance, do mid-sized European players receive more licensing dollars from out-licensing than they spend on in-licensing?
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports